Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05649956 · ClinicalTrials.gov registry record · Phase 2
Letrozole in Uterine Leiomyosarcoma
A Phase 2 study of Uterine Leiomyosarcoma, sponsored by GOG Foundation.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 13
- Study locations
NCT05649956: Recruiting Phase 2 study of Uterine Leiomyosarcoma, sponsored by GOG Foundation.
NCT05649956 is a Phase 2 study of Uterine Leiomyosarcoma that is actively recruiting participants, run by GOG Foundation. The registered enrollment target is 40 participants, above the 36-participant average among 3 other Uterine Leiomyosarcoma trials with a reported enrollment target (11% higher). The trial reports 13 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05649956, a Phase 2 study of Uterine Leiomyosarcoma, is actively recruiting participants, sponsored by GOG Foundation.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 13
- Study locations
Study Summary
This is a clinical trial to test letrozole in patients with uterine leiomyosarcoma. The main question is will treatment with letrozole extend progression-free survival in patients. Patients will receive 2/5 mg of letrozole daily.
Conditions Studied
Interventions
- DRUG Letrozole
Study Locations (13)
Colorado
- University of Colorado Cancer Center - Anschutz Cancer Pavilion - Aurora
- Highlands Ranch Hospital - Highlands Ranch
Nevada
- Women's Cancer Center of Nevada - Las Vegas
- Women's Cancer Center of Nevada - Las Vegas
Florida
- Mount Sinai Comprehensive Cancer Center - Miami Beach
Illinois
- Endeavor Health - Kellogg Cancer Center - Evanston
Louisiana
- WK Physician Network-Gynecologic Oncology Associates - Shreveport
Massachusetts
- University of Massachusetts Memorial Medical Center - Worcester
New Mexico
- University of New Mexico Comprehensive Cancer Center - Albuquerque
North Carolina
- East Carolina University Health Medical Center - Greenville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-07-17 |
| Est. Completion | 2029-07-30 |
| Phase | Phase 2 |
What NCT05649956 shows while recruiting
NCT05649956 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, above the 36-participant average among 3 other Uterine Leiomyosarcoma trials with a reported enrollment target (11% higher).
The record links to 1 condition, with Uterine Leiomyosarcoma appearing as the primary indexed condition, and to 1 intervention - of which Letrozole is the first listed.
NCT05649956 lists 13 locations in 11 states (Colorado, Nevada, Florida).
Frequently Asked Questions
What is clinical trial NCT05649956 about?
NCT05649956 is a clinical study titled "Letrozole in Uterine Leiomyosarcoma". This is a clinical trial to test letrozole in patients with uterine leiomyosarcoma. The main question is will treatment with letrozole extend progression-free survival in patients. Patients will receive 2/5 mg of letrozole daily.
What is the current status of trial NCT05649956?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2024-07-17. Estimated completion is 2029-07-30.
What conditions does trial NCT05649956 study?
This clinical trial studies the following conditions: Uterine Leiomyosarcoma.
What interventions are being tested in trial NCT05649956?
The interventions under investigation include: Letrozole (DRUG).
Who is sponsoring clinical trial NCT05649956?
This trial is sponsored by GOG Foundation, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05649956 being conducted?
This trial has 13 study locations across Colorado, Florida, Illinois, Louisiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uterine Leiomyosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase II Decentralized Pragmatic Trial of Adjuvant Doxorubicin - Trabectedin Chemotherapy in uLMS
RECRUITING · Phase 2
-
CytoreductiveSurgery & HIPEC w/Gemcitabine+Chemotherapy w/Dacarbazine in Uterine Leiomyosarcoma
ACTIVE NOT RECRUITING · Phase 2
-
Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI